MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Cellectar Biosciences Inc

Open

0.3 3.45

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.28

Max

0.31

Schlüsselkennzahlen

By Trading Economics

Angestellte

11

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+222.58% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-3.4M

10M

Vorheriger Eröffnungskurs

-3.15

Vorheriger Schlusskurs

0.3

Cellectar Biosciences Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

11. Dez. 2024, 18:44 UTC

Wichtige Markttreiber

Cellectar Biosciences Plunges on Pursuit of Strategic Options for Cancer Drug Candidate, 60% Workforce Cut

Peer-Vergleich

Kursveränderung

Cellectar Biosciences Inc Prognose

Kursziel

By TipRanks

222.58% Vorteil

12-Monats-Prognose

Durchschnitt 1 USD  222.58%

Hoch 1 USD

Tief 1 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Cellectar Biosciences Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

1

Buy

1

Halten

0

Sell

Finanzen

$

Über Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.